Phio Pharmaceuticals Corp. (PHIO)
- Previous Close
0.7045 - Open
0.7009 - Bid 0.6737 x 200
- Ask 0.7034 x 200
- Day's Range
0.6512 - 0.7009 - 52 Week Range
0.5000 - 6.8500 - Volume
84,641 - Avg. Volume
432,488 - Market Cap (intraday)
3.178M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-5.2000 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
www.phiopharma.comRecent News: PHIO
Performance Overview: PHIO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHIO
Valuation Measures
Market Cap
3.18M
Enterprise Value
-5.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.86%
Return on Equity (ttm)
-116.60%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.83M
Diluted EPS (ttm)
-5.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.49M
Total Debt/Equity (mrq)
0.45%
Levered Free Cash Flow (ttm)
-6.53M
Research Analysis: PHIO
Company Insights: PHIO
PHIO does not have Company Insights